Neisseria meningitidis infection: Who, when and where?

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 10, 2015, Pages 1249-1263

  Gianchecchi, Elena ^a   Torelli, Alessandro ^a   Piccini, Giulia ^a   Piccirella, Simona ^a   Montomoli, Emanuele ^a,b  

^a VisMederi Srl   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

epidemiology; hypervirulent clonal complexes; invasive meningococcal disease; Neisseria meningitidis; single nucleotide polymorphisms

Indexed keywords

BACTERIAL VACCINE; NEISSERIA MENINGITIDIS VACCINE; UNCLASSIFIED DRUG;

ASIA; ASYMPTOMATIC INFECTION; AUSTRALIA; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CARRIER; CANADA; CENTRAL NERVOUS SYSTEM INFECTION; DEATH; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; ENDEMIC DISEASE; EPIDEMIC; EUROPE; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEREDITY; HOST PATHOGEN INTERACTION; HUMAN; INCIDENCE; INFECTION CONTROL; MENINGOCOCCOSIS; MICROBIAL ACTIVITY; NEISSERIA MENINGITIDIS; NEW ZEALAND; NONHUMAN; POPULATION RESEARCH; PREVALENCE; REVIEW; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AND CENTRAL AMERICA; UNITED STATES; HETEROZYGOTE; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; RISK FACTOR;

CARRIER STATE; EUROPE; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; RISK FACTORS;

EID: 84941734707     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1070096     Document Type: Review

References (170)

1. Janda WM, Knapp JS. Neisseria, Moraxella catarrhalis. Manual of clinical microbiology; Washington, DC: 2003
2. Apicella MA. Neisseria meningitidis. Elsevier Churchill Livingstone Publishers; Philadelphia 2005
3. Schoen C, Kischkies L, Elias J, et al. Metabolism and virulence in Neisseria meningitidis. Front Cell Infect Microbiol 2014;114(4):1-16
4. Marchiafava E, Celli A. Sopra i micrococchi della meningite cerebrospinale epidemica. Gazz degli Ospedali 1884;5:59
5. Weichselbaum A. Ueber die Aetiologie der akuten meningitis cerebro-spinalis. Fortschr Med 1887;5:573-83
6. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000;13(1):144-66
7. Har rison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006;19(1):142-64
8. Davidsen T, Koomey M, Tønjum T. Microbial genome dynamics in CNS pathogenesis. Neuroscience 2007;145(4): 1375-87
9. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106(5):505-25
10. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
11. Linz B, Schenker M, Zhu P, et al. Frequent interspecific genetic exchange between commensal Neisseriae and Neisseria meningitidis. Mol Microbiol 2000;36(5): 1049-58
12. Davidsen T, Tønjum T. Meningococcal genome dynamics. Nature Rev Microbiol 2006;4(1):11-22
13. Borst P, Greaves DR. Programmed gene rearrangements altering gene expression. Science 1987;235(4789):658-67
14. Vernikos G, Medini D. Bexsero-chronicl e. Pathog Glob Health 2014;108(7):305-16
15. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcemia and Neisseria meningitidis. Lancet 2007; 369(9580):2196-210
16. Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013;19:566-73
17. Swartley JS, M arfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94(1):271-6
18. Rosenstein NE, Bradley BA, Stephens DS, et al. Meningococcal Disease. N Engl J Med 2001;344(18):1378-88
19. Brandtzaeg P, van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol 2012;799: 21-35
20. Maiden MC. Multilocus sequence typing of bacteria. Annu Rev Microbiol 2006;60: 561-58
21. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-Associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microb iol 2004;42:5146-53
22. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009;27(Suppl 2):B71-7
23. Cartwright KA,Stuart JM,Jones DM,et al. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica Epidemiol Infect 1987 99 3)591-601
24. Brandtzaeg P. Pathogenesis and pathophysiology of invasive meningococcal disease. Handbook of Meningococcal Disease; Weinheim, Germany: 2006
25. Trivedi K, Tang CM, Exley RM. Mechanisms of meningococcal colonisation. Trends Microbiol 2011;19(9):456-63
26. Pizza M, Rappuoli R. Neisseria meningitidis: pathogenesis and immunity. Curr Opin Microbiol 2015;23:68-72
27. Trotter CL, Gay NJ, Ed munds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006;134(3): 556-66
28. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009;9(7): 418-27
29. Lewis LA, Vu DM, Vasudhev S, et al. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. M Bio 2013;4(5):e00339-13
30. Brooks R, Woods CW, Benjamin DK. Jr., et al. Increased case-fatality rate associated with outbreaks of Ne isseria meningitidis infection, compared with sporadic meningococcal disease. in the United States, 1994-2002. Clin Infect Dis 2006;43(1):49-54
31. Black S, Pizza M, Nissum M, et al. Toward a meningitis-free world. Sci Transl Med 2012;4(123):123-5
32. Atkinson W, Wolfe S, Hamborsky J. Centers for Disease Control and Prevention meningococcal disease. The pink book: epidemiology and preventio n of vaccine-preventable diseases. 12th edition. Public Health Foundation; Washington, DC: 2011
33. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001;344(18):1378-88
34. Smirnova I, Mann N, Dols A, et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 2003;100(10):607 5-80
35. Lemee L, Hong E, Etienne M, et al. Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis. PLoS One 2014;9(9):e107240
36. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969;129(6):1327-48
37. Rake G, Scherp HW. Studies on meningococcal infection. III. The antigenic complex of the meningococcus-A type specific substance. J Exp Meal 1933;58:341
38. Vermont CL, de Groot R , Hazelzet JA. Bench-to-bedside review: genetic influences on meningococcal disease. Crit Care 2002; 6(1):60-5
39. Späth PJ, Sjöholm AG, Fredrikson GN, et al. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 1999;118(2):278-84
40. Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000;120(2):33 8-45
41. Mayatepek E, Grauer M, Hansch GM, et al. Deafness, complement deficiencies and immunoglobulin status in patients with meningococcal diseases due to uncommon serogroups. Pediatr Infect Dis J 1993; 12(10):808-11
42. Fijen CA, Kuijper EJ, te Bulte MT, et al. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999;28(1): 98-105
43. Sjoholm AG, Braconier JH, Soderstrom C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 1982;50(2):291-7
44. Lear S,Eren E,Findlow J,et al. Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin J Clin Pathol 2006,59,11)1191-3
45. Emonts M, Hazelzet JA, deGroot R, et al. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003;3(9):565-77
46. van Well GT, Sanders MS, Ouburg S, et al. Polymorphisms in Toll-like receptors 2, 4, and 9 are highly associated with hearing loss in survivors of bacterial meningitis. PLoS One 2012;7(5):e35837
47. van Well GT, Sanders MS, Ouburg S, et al. Sing le nucleotide polymorphisms in pathogen recognition receptor genes are associated with susceptibility to meningococcal meningitis in a pediatric cohort. PLoS One 2013;8(5):e64252
48. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999;353( 9158): 1049-53
49. Read RC, Pullin J, Gregory S, et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001;184(5):640-2
50. Faber J, Henninger N, Finn A, et al. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr 2009; 98 (3):548-52
51. Chauhan VS, Sterka DG, Furr SR, et al. NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia 2009;57(4): 414-23
52. Sanders MS, van Well GT, Ouburg S, et al. Toll-like receptor 9 polymorphisms are associated with severity variables in a cohort of meningococcal meningitis survivors. BMC Infect Dis 2012;12:112
53. Sjölinder H, Mogensen TH, Kilian M, et al. Important role for Toll-like receptor 9 in host defense against meningococcal sepsis. Infect Immun 2008;76(11):5421-8
54. Davila S, Wright VJ, Khor CC. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010;42(9):772-6
55. Abad R, Lopez EL, Debbag R, et al. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect 2014;142(12):2461-70
56. World Health O rganization Working Group Control of epidemic meningococcal diseases: WHO practical guidelines Edition Foundation Marcel Merieux. Lyon, France: 1995
57. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180(6): 1894-901
58. Cartwright KA, Stuart JM, Jones DM, et al. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987;99(3): 591-601
59. Yazdankhah SP, Caugant D. Neisseria meningitidis: An overview of the carriage state. J Med Microbiol 2004;53(Pt 9): 821-32
60. Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis 2013;57(3):344-8
61. Aguilar-GarcáJ, Olalla-Sierra J, Perea-Milla E, et al. Analysis of the epidemiological characteristics and prognostic factors in probable or confirmed invasive meningococcal disease in a cohort of adolescents and adults during an epidemic outbreak. Rev Clin Esp 2009; 209(5):221-6
62. Jardine A, Truman G, Sheppeard V, et al. A community outbreak of meningococcal serogroup B disease in western Sydney: the challenges of identification and significance. Commun Dis Intell Q Rep 2009;33(2): 221-4
63. Martínez AI, Dominguez A, Oviedo M, et al. Meningococcal Disease Working Group of Catalonia. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain). Vaccine 2009;27(25-26):3496-8
64. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013;11(1):17
65. Skoczyńska A, Was̈ko I, Kuch A, et al. A decade of invasive meningococcal disease surveillance in Poland. PLoS One 2013; 8(8):e71943
66. Bijlsma MW,Bekker V,Brouwer MC,et al. Epidemiology of invasive meningo coccal disease in the Netherlands 1960-2012: an analysis of national surveillance data. Lancet Infect Dis 2014 14 9)805-12
67. Stuart JM, Cartwright KA, Jones DM, et al. An outbreak of meningo coccal disease in Stonehouse: planning and execution of a large-scale survey. Epidemiol Infect 1987; 99(3):579-89
68. Chatt C, Gajraj R, Hawker J, et al. Four-month outbreak of invasive meningoco ccal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping. England 2013.Euro Surveil 2014;19(44):1-7
69. Rouaud P, Perrocheau A, Taha MK, et al. Prolonged ou tbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveil 2006;11(7):178-81
70. Elias J, Schouls LM, van de Pol I, et al. Vaccine preventability of meningococcal clone, Greater Aachen Region. Germany. Emerg Infect Dis 2010;16(3):465-72
71. Martin DR, Walker SJ, Baker MG, et al. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998;177(2):497-500
72. Muscat M, Spiteri G, Calleja N, et al. Invasive meningococcal disease in Malta: an epidemiological overview, 1994-2007. J Med Microbiol 2009;58(Pt 11):1492-8
73. Jounio U, Saukkoriipi A, Bratcher HB, et al. Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol 2012;50(2): 264-73
74. Azzari C, Canessa C, Lippi F, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: implications fo r vaccination timing. Vaccine 2014;32(10):1187-91
75. Available from: www.simi.iss.it/files/Report-MBI.pdf
76. Bechini A, Levi M, Boccalini S, et al. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany. Italy. Vaccine 2012;30(45):6396-4 01
77. Resti M, Micheli A, Moriondo M, et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observatio nal study of children and adolescents with proven pneumococcal infection. Clin Ther 2009;31(6):1266-73
78. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012;30(24): 3710-16
79. Baccarini C, Ternouth A, Wieffer H, et al. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 2013;9(1):162-71
80. Brooks R, Woods CW, Benjamin DK Jr., et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared w ith sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006;43(1): 49-54
81. Centers for Disease Control & Prevention. Serogroup B meningococcal disease-Oregon, 1994. MMWR Morb Mortal Wkly Rep 1995;44(7):121-4
82. Sáfadi MA, Carvalhanas TR, Paula de Lemos A, et al. Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal dise ase, Brazil, 2010. Emerg Infect Dis 2014;20(5):806-11
83. Gabastou JM, Agudelo CI, Brandileone MC, et al. Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005. Rev Panam Salud Publica 2008;24(1):1-15
84. Barra GN, Araya PA, Fernandez JO, et al. Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011. PLoS One 2013; 8(6):e66006
85. Sorhouet Pereira C, Regueira M, Mollerach M. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 2008;57(Pt 3):338-42
86. Chiavetta L, Chavez E, Ruzic A, et al. Surveillance of Neisseria meningitidis in Argentina, 1993-2005: distribution of serogroups, serotypes and serosubtypes isolated from invasive disease. Rev Argent Microbiol 2007;39(1):21-7
87. Ines Agudelo C,Sanabria OM,Ovalle MV. Serogroup Y meningococcal disease Colombia Emerg Infect Dis 2008 14 6) 990-1
88. Sosa J, Llanes R, Guzman D, et al. Typing and susceptibility to penicillin of Neisseria men ingitidis isolated from patients in Cuba (1993-1999). Mem Inst Oswaldo Cruz 2001;96(4):523-5
89. Vyse A, Wolter JM, Chen J, et al. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect 2011;139(7):967-85
90. Zhang X, Shao Z, Zhu Y, et al. Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005. Clin Microbiol Infect 2008;14(6):555-61
91. Horino T, Kato T, Sato F, et al. Meningococcemia without meningitis in Japan. Intern Med 2008;47(17):1543-7
92. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2009. Commun Dis Intell 2010;34(3): 291-302
93. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 to 2007. Common Dis Intell Q Rep 2010;34: S1-167
94. Baker MG, Martin DR, Kieft CE, et al. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37(5):S13-19
95. O'Hallahan J, Lennon D, Oster P, et al. From secondary prevention to primary pre vention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23(17-18):2197-201
96. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004;23(12):S293-8
97. Martin D, McDowell R, Sneyd E, et al. The epidemiology of meningococcal disease in New Zealand in 2 002. Report prepared for the Ministry of Health by the Institute of Environmental Research Limited (ESR); Wellington, New Zealand: 2003
98. Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J 2000;19(10): 983-90
99. Loring BJ, Turner N, Petousis-Harris H. MeNZB vaccine and epidemic control: when do you stop vaccinating? Vaccine 2008;26(47):5899-904
100. Fazio C, Neri A, Tonino S, et al. Characterization of Neisseria meningitidis C strains causing two clusters in the north of Ital y in 2007 and 2008. Euro Surveill 2009; 14(16):1-2
101. Mastrantonio P, Stefanelli P, Fazio C, et al. Serotype distribution, antibiotic susceptibility, and genetic relatedness of Neisseria mening itidis strains recently isolated in Italy. Clin Infect Dis 2003;36(4): 422-8
102. Stefanelli P, Fazio C, Neri A, et al. Cluster of invasive Neisseria meningitidis infections on a cruise ship, Italy, October 2012. Euro Surveill 2012;17(50):1-2
103. Stefanelli P, Fazio C, Sofia T, et al. Serogroup C meningococci in Italy in the era of conjugate menC vaccination. BMC Infect Dis 2009;9:135
104. Racoosin JA, Whitney CG, Conover CS, et al. Serogroup Y meningococcal disease in Chicago 1991-1997. JAMA 1998;280(24): 2094-8
105. Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995;273(5):383-9
106. Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004;30(3):17-28
107. Tyrrell GJ, Chui L, Johnson M, et al. Edmonton Meningococcal Study Group. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002;8(5):519-21
108. Chacon-Cruz E,Espinosa-De Los Monteros LE,Navarro-Alvarez S,et al. An outbreak of serogroup C (ST-11) meningococcal disease in Tijuana Mexico. Ther Adv Vaccines 2014 2 3) 71-6
109. Barroso DE, Castiñeiras TM, Freitas FS, et al. Three outbreak-causing Neisseria meningitidis serogroup C clones, Brazil(1.). Emerg Infect Dis 2013;19(11):1847-50
110. Tauil Mde C, Carvalho CS, Vieira AC, et al. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil. Braz J Infect Dis 2014; 18(4) :379-86
111. Shan X, Zhou H, Zhang J, et al. Application of multiple-locus variable number tandem repeat analysis to identify outbreak-Associated neisseria meningitidis serogroup C sequence Type 4821 in China. PLoS One 2015;10(1):e0116422
112. Oberti J, Hoi NT, Caravano R, et al. An epidemic of meningococcal infection in Vietnam (southern provinces). Bull World Health Organ 1981;59(4):585-90
113. Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007;186(3):136-41
114. Halper in SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012;30(Suppl 2):B26-36
115. Koroleva IS, Platonov AE, van Der Ende A, et al. Characteristics of pathogenic Neisseria meningitidis in Moscow: prevalence of 'non-European ' strains. Clin Microbiol Infect 1998;4(3):123-8
116. Souza de Morais J, Munford RS, Risi JB, et al. Epidemic disease due to serogroup C Neisseria meningitidis in Sao Paulo. Brazil. J Infect Dis 1974;129(5):568-71
117. de Moraes JC, Barata RB. Meningococcal disease in Sao Paulo, Brazil, in the 20th century: epidemiological characteristics. Cad Saude Publica 2005;21(5):1458-71
118. Wang JF, Caugant DA, Li X, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 1992; 60(12):5267-82
119. Greenwood BM, Bradley AKJ, Smith AW, et al. Mortality from meningococcal disease during an epidemic in the Gambia, West Africa. Trans R Soc Trop Med H yg 1987; 81(4):536-8
120. Achtman M. Global epidemiology of meningococcal disease. Meningococcal Disease; New York: 1995
121. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93(4):341-53
122. Molesworth AM, Thomson MC, Connor SJ, et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in A frica. Trans R Soc Trop Med Hyg 2002; 96(3):242-9
123. Outbreak news. Meningococcal disease, African meningitis belt, epidemic season 2006. Wkly Epidemiol Rec 2006;81(13): 119-20
124. Xie O, Pollard AJ, Mueller JE, et al. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013;31(27):2852-61
125. Lapeyssonnie L. La me-ningite ce-re bro-spinale en Afrique. Bull WHO 1963;28:3-114
126. Greenwood BM. The epidemiology of acute bacterial meningitis in tropical Africa. Bacterial meningitis; London, UK:1987130.
127. Riedo FX, Plikaytis BD, Broom e CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995;14(8):643-57
128. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the i dentification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998;95(6):3140-5
129. Molesworth AM, Cuevas LE, Connor SJ, et al. Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis 2003; 9(10):1287-93
130. Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health 2013; 107(7):373-80
131. Aguilera JF,Perrocheau A,Meffre C,et al. W135 working Group. Outbreak of the serogroup W135 meningococcal disease after the Hajj pilgrimage Europe 2000. Emerg Infect s Dis 2002 8 8)761-7
132. Djibo S, Nicolas P, Alonso JM, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003;8(12):1118-23
133. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in. 2006 in Niger. Clin Infect Dis 2007;44(5): 657-63
134. Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002;185(5):618-26
135. Materu S, Cox HS, Isaakidis P, et al. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 13 2007; 13(6):944-5
136. Njanpop Lafourcade BM, Tamekloe TA, Snou O, et al. Serogroup X meningococcal meningitis in Togo during 2007 and 2008 abstract P140. International Pathogenic Neisseria Conference; 7-12 September 2008; Rotterdam, Netherlands
137. Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl A cad Sci U S A 2013;110(47):19077-82
138. Racoosin JA, Whitney CG, Conover C, et al. Serogroup Y meningococcal disease in Chicago. 1991-1997. JAMA 1998;280(24): 2094-8
139. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999;353(9157):941-2
140. Vázquez JA, Abad R, Agudelo CI, et al. Molecular cha racterization of invasive serogroup Y Neisseria meningitidis strains isolated in Latin American Region. International Pathogenic Neisseria Conference; 7-12 September 2008; Rotterdam, Netherlands
141. Fijen CAP, Kuijper E J, Tjia HG, et al. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis 1994;18(5):780-4
142. Törös B, Thulin Hedberg S, Jacobsson S, et al. Surveillance of invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill 2014; 19(42):20940
143. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015;60(4):578-85
144. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007;31(1):27-36
145. Popovic T, Sacchi CT, Reeves MW, et al. Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 2000; 6(4):428-9
146. Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000;365(9248):2159
147. Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002;2(12):763-5
148. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 185 2002;185(11):1596-605
149. Taha MK, Parent Du Chatelet I, Schlumberger M, et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002;40(3):1083-4
150. Taha MK, Giorgini D, Ducos-Galand M, et al. Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after e mergence of the serogroup in 2000. J Clin Microbiol 2004;42(9):4158-63
151. Kwara A, Adegbola RA, Corrah PT, et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisse ria meningitidis in West Africa. Trop Med Int Health 1998;3(9):742-6
152. Wilder-Smith A,Goh KT,Barkham T,et al. Hajj-Associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers Clin Infect Dis 2003 36 6) 679-83
153. Traore Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006;43(7): 817-22
154. Adjogble KL, Lourd M, Njanpop-Lafo urcade BM, et al. The epidemiology of Neisseria meningitidis meningitis in Togo during 2003-2005. Vaccine 2007;25(Suppl 1):A47-52
155. Guibourdenche M, Chippaux JP, Ouedraogo-Traore R, et al. Evolution of the second pandemic due to strains of Neisseria meningitidis A:4:P1.9/clone III-I. Survey in four African countries: Niger, Burkina Faso; October 1995-May 1996; Cameroon and Chad
156. Rinaudo CD, Telfo rd JL, Rappuoli R, et al. Vaccinology in the genome era. J Clin Invest 2009;119(9):2515-25
157. Taha MK, Deghmane AE. Meningococcal carriage: the dilemma of 4CMenB vaccine. Lancet. 2014;384(9960):2088-90
158. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-76
159. Nedelec J, Boucraut J, Garnier JM, et al. Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B m eningitis. J Neuroimmunol 1990;29:49-56
160. Bansal V, Kumar M, Dalela M, et al. Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy. Int J Pharm 2014;471: 377-84
161. Leca M, Bornet C, Montana M, et al. Meningococcal vaccines: Current state and future outlook. Pathol Biol 2015;63(3): 144-51
162. Yogev R, Tan T. Meningococcal disease: the advances and challenges of meningococcal disease prevention. Hum Vaccin 2011;7: 828-37
163. Schubert-Unkmeir A, Christodoulides M. Genome-based bacterial vaccines: current state and future outlook. BioDrugs 2013;27: 419-30
164. Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine 2015;33(23):2629-36
165. Vesikari T, Esposito S, Prymu la R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lan cet 2013;381:825-35
166. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24
167. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107(45):19490-5
168. Snape MD, Medini D, Halperin SA, et al. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012;30:B67-72
169. FDA. Trumemba highlights of prescribing information 2014. Available from: www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139. pdf
170. Whelan J, Bambini S, Biolchi A, et al. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives. Expert Rev Vaccines 2015;14(5):713-36